Table 1.

Participant characteristics at baseline*

		HIV+	HIV−	P value
		N=66	N=56
Immunotherapy type	Pembrolizumab	46 (70)	0 (0)
	Bintrafusp alfa	0 (0)	56 (100)
	Durvalumab	20 (30)	0 (0)
CD4 cells/µL		320 (210–495)	356 (260–470)	0.5†
CD4 count categories	<350	36 (55)	23 (50)	0.6
	≥350	30 (45)	23 (50)
CD4 count categories	<200	14 (21)	7 (15)	0.7
	200–350	22 (33)	16 (35)
	>350	30 (45)	23 (50)
Cancer type	Other	31 (47)	0 (0)	<0.001
	Virus-associated	35 (53)	56 (100)
HPV-associated	Non-HPV-associated	56 (85)	56 (100)	0.002
	HPV-associated	10 (15)	0 (0)
Number of prior systemic cancer therapies	0	16 (24)	0 (0)	<0.001
	1–2	25 (38)	43 (77)
	3	11 (17)	11 (20)
	≥4	14 (21)	2 (4)
Number of prior systemic cancer therapies		2 (1–3)	2 (1–2)	0.6
Prior radiotherapy	No	56 (85)	8 (14)	<0.001
	Yes	10 (15)	48 (86)
Age (years)		54.0 (47.0–60.0)	58.0 (48.0–64.6)	0.3
Sex	Male	58 (88)	20 (36)	<0.001
	Female	8 (12)	36 (64)
Race	Black	18 (27)	3 (5)	0.009
	White	43 (65)	46 (82)
	Native Hawaiian or other Pacific Islander	1 (2)	0 (0)
	Asian	0 (0)	2 (4)
	Multiracial	0 (0)	2 (4)
	Not specified	4 (6)	3 (5)
Ethnic group	Hispanic or Latino	25 (38)	6 (11)	0.003
	Not Hispanic or Latino	40 (61)	48 (86)
	Not Reported	1 (2)	2 (4)
Absolute neutrophil count, ×1000/µL		3.6 (2.7–4.7)	4.0 (3.0–5.4)	0.2
Absolute lymphocyte count, ×1000/µL		1.4 (1.0–1.9)	0.9 (0.6–1.4)	0.001

*Data are presented as n (%) or median (IQR).

†Two-sample Wilcoxon rank-sum (Mann-Whitney) test.

HPV, human papillomavirus.